IBIOiBio, Inc.
- GlobeNewswire
iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, ...
- GlobeNewswire
iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer
SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today ...
- GlobeNewswire
iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study
Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach When combined with semaglutide, IBIO-610 drove greater visceral and ...
- Analyst Upgrades
Raymond James Initiates Coverage On iBio with Outperform Rating, Announces Price Target of $5
Raymond James analyst Martin Auster initiates coverage on iBio with a Outperform rating and announces Price Target of $5. ...
- GlobeNewswire
iBio to Participate in Upcoming Healthcare Investor Conferences
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO) ("iBio" or the "Company"), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced ...
- GlobeNewswire
iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity
IBIO-600 is potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition First-in-human study of IBIO-600 to evaluate safety, tolerability, ...
- GlobeNewswire
iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update
Received regulatory clearance to initiate its Phase 1 clinical trial of IBIO-600 in Australia Announced a strategic pipeline expansion into pulmonary hypertension associated with heart failure with preserved ejection ...
- GlobeNewswire
iBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors
SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases announced today the appointment of Elizabeth ...
- GlobeNewswire
iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia
IBIO-600 is a potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body compositionFirst participants expected to be dosed in 2Q 2026 SAN DIEGO, April 08, ...
- GlobeNewswire
iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
SAN DIEGO, March 16, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced the Company will host a ...
- GlobeNewswire
iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss
SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced new preclinical data from ...
- Analyst Upgrades
Jones Trading Initiates Coverage On iBio with Buy Rating, Announces Price Target of $7
Jones Trading analyst Catherine Novack initiates coverage on iBio with a Buy rating and announces Price Target of $7. ...
- GlobeNewswire
iBio to Participate in Upcoming Investor Conferences
SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced that Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief ...
- Analyst Upgrades
Chardan Capital Maintains Buy on iBio, Maintains $5 Price Target
Chardan Capital analyst Keay Nakae maintains iBio with a Buy and maintains $5 price target. ...
- GlobeNewswire
iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update
Secured $26 Million in PIPE Financing Led by a Top-Tier Biotech Investor to Advance Preclinical Programs and Extend Cash Runway Progressed Pipeline with New Preclinical Data and Scientific Presentations at Leading ...
- GlobeNewswire
iBio Announces $26 Million Private Placement
SAN DIEGO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced that it has entered into a securities purchase agreement with existing ...
- GlobeNewswire
iBio to Participate in the 8th Annual Evercore Healthcare Conference
SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced that it will participate in the 8th Annual Evercore Healthcare Conference, ...
- GlobeNewswire
iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update
Strengthened cash position and extended runway into the fourth quarter of fiscal year 2027 after closing underwritten public offering with up to potentially $100 million of total gross proceeds Presented non-human ...
- GlobeNewswire
iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance
Previously reported data showed that in a diet-induced obesity mouse model, IBIO-610 drives fat-selective, GLP-1-synergistic weight loss and prevents weight regain following GLP-1 treatment discontinuation New non-human ...
- GlobeNewswire
iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced that it will participate in the Guggenheim 2nd Annual Healthcare Innovation ...
- GlobeNewswire
iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025
SAN DIEGO, Oct. 21, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced that Cory Schwartz, Ph.D., Director of Research and Early Development at ...
- Analyst Upgrades
Oppenheimer Initiates Coverage On iBio with Outperform Rating, Announces Price Target of $5
Oppenheimer analyst Jay Olson initiates coverage on iBio with a Outperform rating and announces Price Target of $5. ...
- Analyst Upgrades
Leerink Partners Initiates Coverage On iBio with Outperform Rating, Announces Price Target of $2
Leerink Partners analyst Roanna Ruiz initiates coverage on iBio with a Outperform rating and announces Price Target of $2. ...
- SEC
ARS Form - Annual Report to Security Holders - iBio, Inc. (0001420720) (Filer)
Annual Report to Security Holders ...
- SEC
DEF 14A Form - Other definitive proxy statements - iBio, Inc. (0001420720) (Filer)
Other definitive proxy statements ...